Scinovex
review Open AccessTop 1% cited

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Diabetes Care · 2019 · Vol. 42(8) · pp. 1593–1603
Tadej BattelinoThomas DanneRichard M. BergenstalStephanie A. AmielRoy W. BeckTorben BiesterEmanuele BosiBruce A. BuckinghamWilliam T. CefaluKelly L. CloseClaudio CobelliEyal DassauJ. Hans DeVriesKim C. DonaghueKlemen DovčFrancis J. DoyleSatish K. GargGeorge GrunbergerSimon HellerLutz HeinemannIrl B. HirschRoman HovorkaWeiping JiaOlga KordonouriBoris KovatchevAaron J. KowalskiLori M. LaffelBrian J. LevineAlexander Yur'evich MayorovChantal MathieuHelen MurphyRevital NimriKirsten NørgaardChristopher G. ParkinÉric RenardDavid RodbardBanshi SabooDesmond SchatzKeaton StonerTatsuiko UrakamiStuart A. WeinzimerMoshe Phillip

Abstract

Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.

Diabetes Management and ResearchHyperglycemia and glycemic control in critically ill and hospitalized patientsPancreatic function and diabetesMedicineContinuous glucose monitoringInterpretation (philosophy)Diabetes mellitusConsensus conferenceIntensive care medicineMEDLINEInternal medicineType 1 diabetesEndocrinology

MeSH terms

Data AccuracyBlood GlucoseData Interpretation, StatisticalDiabetes MellitusGlycated HemoglobinHumansPatient Care PlanningReference ValuesTime FactorsBlood Glucose Self-MonitoringPractice Guidelines as TopicConsensusInternationality

Funding

  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Leona M. and Harry B. Helmsley Charitable Trust
  • University of Virginia
  • Insulet Corporation
  • MannKind Corporation
  • Dexcom
  • OPKO Health
  • Universiteit van Amsterdam
  • KU Leuven
  • Novo Nordisk
  • Roche Diabetes Care
  • National Institutes of Health
  • U.S. Food and Drug Administration
  • Abbott Diabetes Care
  • National Cancer Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.